|
V.BTI
|
Thanks bfw for posting this. I had the opportunity to view the filing...
|
|
V.BTI
|
In response to recent posts referencing my June post, it's probably time...
|
|
V.BTI
|
It has been almost 6 weeks since Dr. Mark Day took over as CEO. From a...
|
|
V.BTI
|
In a nutshell, biOasis must demonstrate that it's technology has been...
|
|
V.BTI
|
Just some thoughts on the licensing deal with Vaccinex. Since Vaccinex...
|
|
V.BTI
|
From the Alexion 2015 earnings call transcript – February 3, 2016 (Martin...
|
|
V.BTI
|
From the Alexion 2015 earnings call transcript February 3, 2016 (Martin...
|
|
V.BTI
|
Over the past year, BTI has traded approximately 14 million shares at an...
|
|
V.NEV
|
Guess I should do a better job of editing before posting: Paragraph 5...
|
|
V.NEV
|
Had the opportunity over the past few weeks to complete my due diligence on...
|
|
V.BTI
|
Looking at the CNS charts from the recent Scarpa video, one can easily see...
|
|
V.BTI
|
Biogen Aducanumab Dosing on this seems to be everything. From...
|
|
V.BTI
|
At the moment, it seems to be worth $1.20 per share. If you apply traditional...
|
|
V.BTI
|
Came across this recently on the FierceDrugDelivery site:GSK exec stresses...
|
|
V.BTI
|
At the moment, one of the fastest growing areas in pharmaland is that of gene...
|
|
V.BTI
|
Perhaps the most recent significant catalysts for biOasis are the hiring of...
|
|
V.BTI
|
It is absolutely remarkable how some of these articles are written:
"...
|
|
V.BTI
|
According to the latest video presentation, the treatment of Lysosomal...
|
|
V.BTI
|
Should point out as well, that you will have more that crosses into the...
|
|
V.BTI
|
Interesting discussion taking place. There are some relevant articles that...
|